Thus, regulating TRPML1 activity might be an effective therapeutic approach for the treatment of other neurological disorders where low TRPML1 activity has been reported, such as ALS (Tedeschi et al., 2019), Parkinson disease (Tsunemi et al., 2019), Alzheimer’s Disease (Zhang et al., 2017), and Niemann-Pick disease (Shen et al., 2012). This evidence concerns the gene MCOLN1 and early-onset autosomal dominant Alzheimer disease.